Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…Do Peripheral Inflammatory Markers Predict Impulse Control Disorders in Parkinson’s Disease? Insights from a Retrospective Study
Objective: To evaluate the relationship between hematological inflammatory markers—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)—and ICD development in PD patients treated with…Comparing the Impact of Levodopa versus Pramipexole on Eye-Tracking Parameters in Treatment-Naïve Parkinson’s Disease: A Longitudinal Study
Objective: To investigate the differential effects of levodopa versus pramipexole on eye-tracking parameters in treatment-naïve patients with Parkinson's disease. Background: Parkinson's disease (PD) is characterized…Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301
Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…Mortality and Institutionalisation Following de Novo Use of Rotigotine Patches in Hospitalised Patients with Parkinson’s Disease
Objective: Guidelines recommend use of rotigotine patches as an option if Parkinson’s patients are unable to take their usual oral medication, but this strategy has…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Course of Impulse Control Disorder in People Living with Parkinson’s Disease: A Longitudinal Study on Dopamine Agonist Treatment
Objective: To compare the incidence and severity of ICDs among PwP treated with different DA, specifically examining their respective impacts on ICD onset and remission.…Dopa-Responsive Parkinsonism Secondary to Tauopathy: Clinical, Pathological, and Genetic Study
Objective: To report on the clinical, pathological, and genetic findings of four cases of levodopa-responsive parkinsonism with long survival and tauopathy. Background: The most common…A Novel Dopaminergic Modulator (NDM-101) as an Adjunct to Levodopa: Enhancing Motor Control Without Worsening Dyskinesia in Parkinson’s Disease
Objective: To evaluate the efficacy and safety of NDM-101 as an adjunct to levodopa in reducing OFF-time, improving motor function, and maintaining quality of life…Changes in Motor States Throughout the Waking Day With Tavapadon in People With Parkinson’s Disease
Objective: To evaluate motor states throughout the waking day when adding tavapadon to oral carbidopa/levodopa in adults with Parkinson’s disease experiencing motor fluctuations. Background: Long-term…
- 1
- 2
- 3
- …
- 15
- Next Page »
